| Drug Name: | Lotiglipron |
| Width: | 280 |
| C: | 31 |
| H: | 31 |
| Cl: | 1 |
| N: | 4 |
| O: | 5 |
| Iupac Name: | 2--3-benzimidazole-5-carboxylic acid| CAS_number = 2401892-75-7| ChemSpiderID = | PubChem = 146609022| UNII = YI10W1K93A| smiles = C[C@@]1(OC2=CC=CC(=C2O1)C3CCN(CC3)CC4=NC5=C(N4C[C@@H]6CCO6)C=C(C=C5)C(=O)O)C7=NC=C(C=C7)Cl| StdInChI = 1S/C31H31ClN4O5/c1-31(27-8-6-21(32)16-33-27)40-26-4-2-3-23(29(26)41-31)19-9-12-35(13-10-19)18-28-34-24-7-5-20(30(37)38)15-25(24)36(28)17-22-11-14-39-22/h2-8,15-16,19,22H,9-14,17-18H2,1H3,(H,37,38)/t22-,31-/m0/s1| StdInChIKey = SVPYZAJTWFQTSM-UGDMGKLASA-N}} Lotiglipron is a non-peptide glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Pfizer.[1] It was withdrawn from development after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.[2] See alsoReferences] |